Lexaria Bioscience (LEXX) News Today $2.20 +0.03 (+1.38%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight LossNovember 13, 2024 | finanznachrichten.deLexaria Bioscience provides GLP-1 industry updateNovember 8, 2024 | markets.businessinsider.comTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 13, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Shares Letter from Outgoing CEOSeptember 10, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) LiraglutideSeptember 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical SettingSeptember 5, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 31, 2024 | theglobeandmail.comHempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 29, 2024 | msn.comLexaria Bioscience Corp.: First Results from Lexaria's Second GLP-1 Human Pilot StudyAugust 28, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Announces Positive Interim Animal Study Results on DehydraTECH-CBD in Diabetes ControlAugust 22, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal StudyAugust 21, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Positive Results from Lexaria's Molecular Characterization StudyAugust 19, 2024 | finanznachrichten.deLexaria Bioscience (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Animal StudyAugust 8, 2024 | theglobeandmail.comLexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen HormoneAugust 4, 2024 | msn.comVanessa Carle Sells 2,567 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) StockAugust 3, 2024 | insidertrades.comLexaria Bioscience Corp. (NASDAQ:LEXX) Insider Vanessa Carle Sells 2,567 SharesLexaria Bioscience Corp. (NASDAQ:LEXX - Get Free Report) insider Vanessa Carle sold 2,567 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $4.00, for a total transaction of $10,268.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.August 1, 2024 | marketbeat.comInvenomic Capital Management LP Sells 258,716 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX)Invenomic Capital Management LP cut its stake in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX - Free Report) by 35.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 473,265 shares of the company's stockJuly 31, 2024 | marketbeat.comLexaria (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study DosingJuly 23, 2024 | theglobeandmail.comBuy Rating for Lexaria Bioscience on Promising DehydraTECH Efficacy and Solid FinancialsJuly 19, 2024 | markets.businessinsider.comBuy Rating on Lexaria Bioscience Fueled by Promising DehydraTECH Advances in Diabetes Drug DevelopmentJuly 19, 2024 | markets.businessinsider.comLexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, EpilepsyMay 23, 2024 | theglobeandmail.comLexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyMay 21, 2024 | finance.yahoo.comLexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal StudyMay 20, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing MarketsMay 17, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 17, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, IssuanceMay 10, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2May 9, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)May 8, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyMay 8, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 DrugsMay 7, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceApril 30, 2024 | finanznachrichten.deLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 17, 2024 | msn.comLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp LEXXApril 5, 2024 | morningstar.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 19, 2024 | theglobeandmail.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 15, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 7, 2024 | finanznachrichten.deLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 5, 2024 | msn.comLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finanznachrichten.de7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.comLexaria slips despite FDA nod to test blood pressure drugMarch 1, 2024 | msn.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 18, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 16, 2024 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finanznachrichten.deLexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | finance.yahoo.comLexaria Bioscience’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 DrugFebruary 13, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) To Hit High Ground in Q2/Q3 2024 with Animal, Human GLP-1 StudiesJanuary 30, 2024 | theglobeandmail.comLexaria's Submits Investigational New Drug ApplicationJanuary 30, 2024 | finance.yahoo.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! LEXX Media Mentions By Week LEXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LEXX News Sentiment▼0.310.46▲Average Medical News Sentiment LEXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LEXX Articles This Week▼01▲LEXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IXHL News Today SGMT News Today CRDL News Today PBYI News Today CRDF News Today SKYE News Today TELO News Today CADL News Today CGEN News Today ADVM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LEXX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts